Monday, May 29, 2023
English News
  • Hyderabad
  • Telangana
  • Andhra Pradesh
  • India
  • World
  • Entertainment
  • Science and Tech
  • Sport
  • Business
  • ...
    • NRI
    • View Point
    • cartoon
    • Columns
    • Reviews
    • Education Today
    • Property
    • Videos
    • Lifestyle
    • Rewind
E-Paper
  • NRI
  • View Point
  • cartoon
  • Columns
  • Reviews
  • Education Today
  • Property
  • Videos
  • Lifestyle
  • Rewind
Home | Lifestyle | Loss Of Anti Tumour Protein May Cause Resistance To Certain Cancer Therapies

Loss of anti-tumour protein may cause resistance to certain cancer therapies

Cells with high amounts of EGFR died when treated with the therapies, while those with normal amounts of EGFR were not affected by the therapies

By ANI
Published Date - 11:37 AM, Tue - 22 December 20
Loss of anti-tumour protein may cause resistance to certain cancer therapies
whatsapp facebook twitter telegram

Washington: The absence of a protein that works to prevent tumour formation may explain why some patients are resistant to common cancer therapy, according to Penn State College of Medicine researchers.

They said that testing cancers for the presence of this protein may help clinicians identify patients who may be resistant to or relapse when treated with the therapy.

Epidermal growth factor receptor (EGFR) is a protein that plays a role in cell division and survival signalling and is active in skin, bladder, esophageal, lung, liver, pancreatic, colon, and head and neck cancers.

Patients with high amounts of this protein in their tumours tend to have a poor prognosis. EGFR-targeting therapies are used in clinical practice and are often initially effective in many patients. However, some patients are resistant to the therapy and many who were initially responsive to treatment relapse within a year.

Douglas Stairs, assistant professor of pathology and laboratory medicine and pharmacology, investigated why these patients may be resistant to EGFR therapies.

He said mutations in the gene that contains the instructions for building EGFR or other genetic and cellular factors account for about 70 per cent of resistance causes.

“There are still some reasons for resistance that are alluding scientists,” said Stairs, a Penn State Cancer Institute researcher. “Our previous work showed that too much EGFR and reduced amounts of a protein called p120 catenin (p120ctn) can cause cancer to develop.

We hypothesized that reduced amounts of p120ctn might also cause resistance to EGFR therapies.” In healthy cells, p120ctn strengthens cell-to-cell contact by cooperating with other proteins to strengthen connections between epithelial cells, which serve as the barrier between the body’s external and internal surfaces.

According to Stairs, scientists know that the cancer cells often have reduced amounts of p120ctn, but are unsure why.To test their hypothesis, Stairs and colleagues cultured genetically-engineered esophageal cancer cells — one set with normal amounts of EGFR and p120ctn, one set with higher amounts of EGFR, one set with lower amounts of p120ctn and another set with high amounts of EGFR and low amounts of p120ctn. They then treated each cell line with a series of EGFR-targeting therapies.

Cells with high amounts of EGFR died when treated with the therapies, while those with normal amounts of EGFR were not affected by the therapies.

The cell lines that had high amounts of EGFR and reduced amounts of p120ctn were resistant — demonstrating that loss of p120ctn is a critical component to the cells’ resistance to EGFR-targeted therapies. The results were published in PLOS ONE.

Stairs said that while these results are promising, his lab will continue to explore the role of p120ctn loss in EGFR therapy resistance by testing the effect in cancer cells sampled from patients with colon, lung, oral or other cancers.

They will also explore whether the cells with increased EGFR and decreased p120ctn are resistant to other EGFR therapies approved by the U.S. Food and Drug Administration.

“We also need to investigate further how the loss of p120ctn causes this resistance,” Stairs said. “For now, we know that if patients who have high levels of EGFR in their samples were also tested for their levels of p120ctn, it may provide a clue to clinicians as to which patients are at risk for resistance to EGFR-targeting therapies or relapse.”

  • Follow Us :
  • Tags
  • anti-tumour protein
  • bladder
  • colon
  • EGFR therapies

Related News

  • Government hospitals first choice for poor in Telangana

    Government hospitals first choice for poor in Telangana

  • Hyderabadi shaadi goes to Bengaluru without a bride or a groom

    Hyderabadi shaadi goes to Bengaluru without a bride or a groom

  • Spend a cool evening with your squad by playing board games at these cafes in Hyderabad

    Spend a cool evening with your squad by playing board games at these cafes in Hyderabad

  • TSPSC question paper leak case: SIT of Hyderabad police arrest one more person

    TSPSC question paper leak case: SIT of Hyderabad police arrest one more person

  • Telangana: Wanaparthy SP office all set for inauguration

    Telangana: Wanaparthy SP office all set for inauguration

  • Telangana: Yellareddy to get 100-bed hospital

    Telangana: Yellareddy to get 100-bed hospital

Latest News

  • Kareena Kapoor adds glamour to Monaco Grand Prix 2023

    10 mins ago
  • Excise Policy scam: Manish Sisodia generated Rs 622.67 cr POC, says ED

    25 mins ago
  • Devotees express anger over Yamuna River’s pathetic state ahead of Ganga Dussehra

    40 mins ago
  • Canal water in Venice turns fluorescent green, authorities launch probe

    1 min ago
  • Formula 1: Verstappen wins Monaco Grand Prix

    14 mins ago
  • Congress slams Centre for ‘breakdown’ of law and order in Manipur

    20 mins ago
  • Mahabubnagar: Govt Polytechnic College gets NBA accreditation

    3 hours ago
  • Telangana: Digital Excellence Centres to come up in public libraries

    3 hours ago

company

  • Home
  • About Us
  • Contact Us

business

  • Subscribe

telangana today

  • Telangana
  • Hyderabad
  • Latest News
  • Entertainment
  • World
  • Andhra Pradesh
  • Science & Tech
  • Sport

follow us

© Copyrights 2022 TELANGANA PUBLICATIONS PVT. LTD. All rights reserved. Powered by Veegam